Resumen:
|
[EN] Potassium levels in the plasma, [Kþ]o, are regulated precisely under physiological conditions. However, increases (from approx. 4.5 to
8.0 mM) can occur as a consequence of, e.g., endurance exercise, ischemic insult ...[+]
[EN] Potassium levels in the plasma, [Kþ]o, are regulated precisely under physiological conditions. However, increases (from approx. 4.5 to
8.0 mM) can occur as a consequence of, e.g., endurance exercise, ischemic insult or kidney failure. This hyperkalemic modulation of
ventricular electrophysiology has been studied extensively. Hypokalemia is also common. It can occur in response to diuretic therapy,
following renal dialysis, or during recovery from endurance exercise. In the human ventricle, clinical hypokalemia (e.g., [Kþ]o levels of
approx. 3.0 mM) can cause marked changes in both the resting potential and the action potential waveform, and these may promote
arrhythmias. Here, we provide essential background information concerning the main Kþ-sensitive ion channel mechanisms that act in
concert to produce prominent short-term ventricular electrophysiological changes, and illustrate these by implementing recent
mathematical models of the human ventricular action potential.
Even small changes (~1 mM) in [Kþ]o result in significant alterations in two different Kþ currents, IK1 and HERG. These changes can
markedly alter in resting membrane potential and/or action potential waveform in human ventricle. Specifically, a reduction in net
outward transmembrane Kþ currents (repolarization reserve) and an increased substrate input resistance contribute to electrophysiological
instability during the plateau of the action potential and may promote pro-arrhythmic early after-depolarizations (EADs).
Translational settings where these insights apply include: optimal diuretic therapy, and the interpretation of data from Phase II and III
trials for anti-arrhythmic drug candidates.
[-]
|
Agradecimientos:
|
In Valencia, this work was supported by: (i) the “Plan Estatal de Investigación Científica y Técnica y de Innovación 2013–2016” from the Ministerio de Economía, Industria y Competitividad of Spain (DPI2016-75799-R) and ...[+]
In Valencia, this work was supported by: (i) the “Plan Estatal de Investigación Científica y Técnica y de Innovación 2013–2016” from the Ministerio de Economía, Industria y Competitividad of Spain (DPI2016-75799-R) and AEI/FEDER, UE, and by the “Programa Prometeu (PROMETEU/2016/088) de la Conselleria d'Educació, Formació I Ocupació, Generalitat Valenciana”. and (v) GileadSciences, Ltd. Wayne Giles acknowledges receipt of financial support in the form of a salary award (Medical Scientist) from Alberta Innovates-Health Solutions, and operating funding from the Canadian Institutes for Health Research and the Heart and Stroke Foundation of Alberta.
[-]
|